Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?

References

• Butler JC, Breiman RF, Lipman HB, et al. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis. 1995;171:885–889.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr. 2010;10:4.
   PubMed Web of Science ®Google Scholar
• Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13(R)]. Drugs. 2010;70:1973–1986.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28:S66–76.
   PubMed Web of Science ®Google Scholar
• Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192–4203.
   PubMed Web of Science ®Google Scholar
• Wijmenga-Monsuur AJ, van Westen E, Knol MJ, et al. Direct comparison of immunogenicity induced by 10- or 13-valent pneumococcal conjugate vaccine around the 11-month booster in Dutch infants. PLoS One. 2015;10:e0144739.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Clinical Study Report for study 116485. [cited 2016 Apr 26]. Available from: http://www.gsk-clinicalstudyregister.com/study/116485?study_ids=116485#rs
   Google Scholar
• Dagan R, Givon-Lavi N, Fraser D, et al. Serum serotype-specific pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis. 2005;192:367–376.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Greenberg D, Leibovitz E, et al. Pneumococcal vaccination near disappearance of antibiotic-resistant pneumococcal otitis media, associated with high PCV7/PCV13 uptake and substantial decrease of PCV13-serotypes nasopharyngeal carriage. 33th Annul Meeting of the European Society of Pediatric Infectious Diseases (ESPID); 2015 May 14-15; Leipzig Germany. OP 0225.
   Google Scholar
• Kandasamy R, Ndimah S, Hughes H, et al. Pneumococcal carriage by children and their parents post-PCV13 introduction in United Kingdom.. 34th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 10-14 2016; Brighton, UK, ESP16-0151
   Google Scholar
• Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012;31:297–301.
   PubMed Web of Science ®Google Scholar
• Van Den Bergh MR, Spijkerman J, Swinnen KM, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2013;56:e30–39.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Sáez-Llorens X, López P, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11:e1001657.
   PubMed Web of Science ®Google Scholar
• Vesikari T Impact of PHiD-CV on bacterial nasopharyngeal carriage in Finnish children: a cluster-randomized controlled trial adapted from oral presentation. 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2013 Apr 29; Berlin, Germany.
   Google Scholar
• Brandileone MC, Zanella RC, Almeida SC, et al. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil. Vaccine. 2016;34:5604–5611.
   PubMed Web of Science ®Google Scholar
• Sigrudsson S, Erlendsdottir H, Hrafnkelsson B, et al. Use of vaccines early herd effect in day care centres after the initiation of the PCV-10 vaccination in Iceland. 34th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2016 May 10-14; Brighton, UK, ESP16-0981.
   Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–309.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Prevenar 13: EPAR - product information. [cited 2016 Mar 23]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000323/human_med_000987.jsp
   Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59:1066–1073.
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2:464–471.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Welfare of Finland. Available from: https://www.thl.fi/en/web/thlfi-en/research-and-expertwork/projects-and-programmes/monitoring-the-population-effectiveness-of-pneumococcal-conjugate-vaccination-in-the-finnish-national-vaccination-programme/incidence-of-invasive-pneumococcal-disease-in-finland.
   Google Scholar
• Cassiolato A, Almeida S, Guerra M, et al. Changes in invasive Streptococcus pneumoniae serotype (Spn) 19A after introduction of 10-valent pneumococcal conjugate vaccine (PCV10) in Brazil. 9th World Congress of the World Society for Pediatric Infectious Diseases (WSPID); 2015 Nov 18-21; Rio de Janeiro, Brazil, WSPID-0664.
   Google Scholar
• Potin M, Fica A, Wilhem J, et al. Statement of the Advisory Immunization Committee of the Chilean Society of Infectious Diseases on the emergence of serotype 19A pneumococcal infection and the use of pneumococcal conjugated vaccine in Chilean children. Rev Chilena Infectol. 2016;33(3):304–306.
   PubMed Web of Science ®Google Scholar
• Castañeda E, Agudelo CI, De Antonio R, et al. Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990–2010. BMC Infect Dis. 2012;12:124.
   PubMed Web of Science ®Google Scholar
• Chacon-Cruz E, Velazco-Mendez Y, Navarro-Alvarez S, et al. Pneumococcal disease: emergence of serotypes 19A and 7F following conjugate pneumococcal vaccination in a Mexican hospital. J Infect Dev Ctries. 2012;6:516–520.
   PubMed Web of Science ®Google Scholar
• Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML. Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines. 2014;2:155–158.
   PubMedGoogle Scholar
• De Wals P, Lefebvre B, Markowski F, et al. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine. 2014;32:1501–1506.
   PubMed Web of Science ®Google Scholar